CHADS2评分在急性ST段抬高型心肌梗死预后评估中的应用价值

Usefulness of the CHADS2 score for prognosis of patients with acute ST-segment elevation myocardial infarction

目的 探讨CHADS2评分对评估急性ST段抬高型心肌梗死（STEMI）患者预后的临床价值.方法 收集2013年5月至2015年12月在乐山市人民医院确诊为STEMI的患者200例,应用CHADS2对患者的基线特征进行评分,随访至少1年或至出现主要心血管不良事件（MACE,包括死亡、非致死性心肌梗死、脑梗死）,依据评分高低与不良事件的发生率评估CHADS2的效率.结果 CHADS2评分越高,STEMI患者发生MACE的风险越高.结论 CHADS2评分是STEMI患者未来发生MACE的独立危险因素,可为STEMI患者的预后提供有价值的信息.

Objective To investigate whether the CHADS2 score has good accuracy for predicting clinical outcome in patients with acute ST-segment elevation myocardial infarction（STEMI）. Methods A total of 200 consecutive patients with STEMI were enrolled in this study from May 2013 to December 2015. The CHADS2 score was calculated for each patient on admission. All patients included in the study were followed up for at least 1 years or until the occurrence of major adverse cardiovascular events （MACE） including death, nonfatal myocardial infarction, and ischemic stroke. Results The incidence of MACE was significantly higher in patients with high CHADS2 scores compared with that in patients with low CHADS2 scores. Conclusion The use of the CHADS2 score is an acceptable method for risk stratification and prognosis of patients with acute STEMI.